Stoke Therapeutics
@stoketherapeutics.com
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.
Stoke Therapeutics's Company Logos
Stoke Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#EFA904
Yellow Sea
239, 169, 4
42, 97, 48
0, 29, 98, 6
#2C2C2B
Tuatara
44, 44, 43
60, 1, 17
0, 0, 2, 83
#DDB99F
Cameo
221, 185, 159
25, 48, 75
0, 16, 28, 13
About Stoke Therapeutics
Stoke Therapeutics is a pioneering biotechnology company dedicated to restoring genetic health through innovative RNA-based therapies. Their proprietary research platform, TANGO, focuses on boosting protein output from healthy genes, providing a unique solution for genetic disorders caused by gene mutations. Stoke's initial therapeutic applications target diseases characterized by haploinsufficiency, where one gene copy functions normally while the other is not, with a primary focus on conditions like Dravet syndrome, a severe genetic epilepsy presenting early in life with challenging seizure episodes.
Stoke is currently advancing clinical research for zorevunersen (STK-001), aimed at modifying the disease's genetic foundation. Additionally, the company is exploring the therapeutic potential of TANGO in treating autosomal dominant optic atrophy and other serious diseases. Stoke Therapeutics is committed to inclusivity and collaboration within their team, fostering an environment that encourages authentic contributions and shared passion for tackling significant health challenges. As they innovate, Stoke aims to redefine treatment possibilities for patients battling severe genetic disorders.
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
